Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04795037 · ClinicalTrials.gov registry record · Phase 1
First-In-Human Study of CU06-1004 Following Single and Multiple Ascending Doses in Healthy Volunteers
A Phase 1 study of Diabetic Macular Edema, sponsored by Curacle Co..
- Completed
- Registry status
- Phase 1
- Development phase
- 81
- Enrollment target
- 1
- Study location
NCT04795037 is a Phase 1 study of Diabetic Macular Edema that has completed, run by Curacle Co.. The registered enrollment target is 81 participants, below the 3,793-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04795037, a Phase 1 study of Diabetic Macular Edema, has completed, sponsored by Curacle Co..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 81 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial is the first-in-human study of CU06-1004. The purpose of this phase 1 study is to assess the safety and tolerability of single and multiple ascending oral doses of CU06-1004 in healthy adult subjects.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG CU06-1004, Single dose
- DRUG CU06-1004, Multiple doses
Study Locations (1)
Nebraska
- Celerion - Lincoln
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2021-07-15 |
| Est. Completion | 2022-06-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04795037
The ClinicalTrials.gov registry entry for NCT04795037 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 81 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,793-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (98% lower). The listed sponsor is Curacle Co., which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetic Macular Edema appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT04795037 reports 1 study location spanning 1 distinct geographic area - top geographies include Nebraska.
Frequently Asked Questions
What is clinical trial NCT04795037 about?
NCT04795037 is a clinical study titled "First-In-Human Study of CU06-1004 Following Single and Multiple Ascending Doses in Healthy Volunteers". This clinical trial is the first-in-human study of CU06-1004. The purpose of this phase 1 study is to assess the safety and tolerability of single and multiple ascending oral doses of CU06-1004 in healthy adult subjects.
What is the current status of trial NCT04795037?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 81 participants. The study started on 2021-07-15. Estimated completion is 2022-06-25.
What conditions does trial NCT04795037 study?
This clinical trial studies the following conditions: Diabetic Macular Edema.
What interventions are being tested in trial NCT04795037?
The interventions under investigation include: Placebo (DRUG), CU06-1004, Single dose (DRUG), CU06-1004, Multiple doses (DRUG).
Who is sponsoring clinical trial NCT04795037?
This trial is sponsored by Curacle Co., which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04795037 being conducted?
This trial has 1 study location across Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Macular Edema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of K9 in Subjects With Diabetic Macular Edema (DME)
RECRUITING · Phase 1
-
EC-104 Intravitreal Implant for the Treatment of Diabetic Macular Edema
RECRUITING · Phase 1
-
Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME)
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema
RECRUITING · Phase 1
-
Kamuvudine-9 (K9) in Diabetic Macular Edema
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With Diabetic Macular Edema (DME)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.